Document ID: T_2_07
Section: T_Psychology_Social
Keywords: addiction psychology, substance use disorder, dopamine reward, incentive sensitization, tolerance, dependence, withdrawal, relapse, craving, behavioral addiction, gambling disorder, dual-process model, impulsivity, compulsivity, self-medication hypothesis, motivational interviewing, cognitive behavioral therapy addiction, harm reduction, 12-step programs, opioid crisis, neuroplasticity addiction
Category Tags: psychology, social, neuroscience
Cross-References: T_3_05 · T_2_06 · T_2_05 · T_3_06 · Z_3_12
Reliability Tier: Tier 1-2 (strong neuroscience and clinical evidence; treatment mechanisms debated)
Last Updated: Mar 07, 2026 | Source Count: 21 | Weighted Score: 42 | Source Confidence: [5/5] | Confidence: High

QUICK SUMMARY

Addiction — compulsive engagement with a substance or behavior despite harmful consequences — is now understood as a chronic brain disorder involving neuroplastic changes in reward, motivation, memory, and executive control circuits.

The incentive sensitization theory (Robinson & Berridge, 1993) distinguishes "wanting" (incentive motivation — mediated by mesolimbic dopamine) from "liking" (hedonic pleasure — mediated by opioid/endocannabinoid systems in nucleus accumbens hotspots). With repeated drug use, the wanting system becomes hypersensitized (drug cues trigger intense craving) while liking diminishes (tolerance) — producing the paradox of compulsive pursuit of something no longer pleasant.

Heritability of addiction is ~40–60% across substances (Goldman et al., 2005), with identified risk variants including ADH1B/ALDH2 (alcohol), OPRM1 (opioids), and CHRNA5 (nicotine). The opioid crisis — responsible for >100,000 US overdose deaths annually by 2022 — demonstrated how pharmaceutical marketing, overprescription, and subsequent supply restriction drove transition to illicit heroin and fentanyl.

Treatment approaches span pharmacological (methadone, buprenorphine, naltrexone for opioids; varenicline for nicotine), psychosocial (CBT, motivational interviewing, contingency management), and mutual-help (12-step programs) — with combination treatments generally most effective.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Archaeological Record)

1.1 Neuroscience of addiction

• Reward circuitry: All drugs of abuse increase dopamine release in the nucleus accumbens — cocaine blocks dopamine reuptake; amphetamines reverse dopamine transporters; opioids disinhibit VTA dopamine neurons via mu-opioid receptors on GABAergic interneurons; alcohol and nicotine act through multiple mechanisms.
• Incentive sensitization (Robinson & Berridge, 1993): Repeated drug exposure sensitizes the mesolimbic dopamine system → drug-associated cues acquire excessive incentive salience (wanting) → compulsive drug-seeking even as hedonic pleasure (liking) diminishes through tolerance. This model explains the "addiction paradox" — continued pursuit of something that is no longer enjoyed.
• Prefrontal dysfunction (Goldstein & Volkow, 2011): Chronic substance use impairs dorsolateral PFC (cognitive control), ventromedial PFC (emotional regulation), and anterior cingulate cortex (conflict monitoring) → reduced capacity for inhibition, decision-making, and salience attribution to non-drug rewards.
• Allostatic model (Koob & Le Moal, 2001): Addiction progresses through three stages: (1) binge/intoxication (reward), (2) withdrawal/negative affect (anti-reward), (3) preoccupation/anticipation (craving) — the hedonic set point shifts downward as stress systems (CRF, norepinephrine, dynorphin) become hyperactive, creating a persistent negative emotional state that drives continued use.

1.2 Genetics of addiction

• Heritability: Twin studies establish addiction heritability at ~40–60% across substances: alcohol ~50%, nicotine ~60%, cannabis ~50%, opioids ~40%, cocaine ~65% (Goldman et al., 2005).
• Specific variants (validated): ADH1B2 and ALDH22 (East Asian "flushing" allele — protective against alcoholism, OR ≈ 0.10–0.25); CHRNA5-A3-B4 nicotinic receptor cluster (rs16969968 — increased smoking heaviness, OR ≈ 1.30); OPRM1 A118G (opioid receptor variant — debated but associated with treatment response).
• Polygenic architecture: GWAS meta-analyses identify hundreds of risk loci, each of small effect — most overlap with psychiatric and behavioral phenotypes (impulsivity, sensation-seeking, negative affect); gene × environment interactions are critical.

1.3 Risk and protective factors

• Risk factors: Early onset of use (before age 15 → 4× addiction risk), family history, adverse childhood experiences (ACEs), comorbid psychiatric disorders (depression, anxiety, ADHD, antisocial personality), trauma, peer substance use, drug availability.
• Protective factors: Stable family environment, parental monitoring, academic engagement, religiosity/spirituality, community resources, delayed age of first use.
• Self-medication hypothesis (Khantzian, 1985): Individuals use specific substances to manage specific emotional states — stimulants for depression and attention deficits, opioids for rage and aggression, alcohol for anxiety; empirically partially supported but oversimplified (many users do not fit predicted drug-emotion matches).

1.4 Evidence-based treatments

• Opioid use disorder: Medication-assisted treatment (MAT) with methadone or buprenorphine reduces overdose mortality by 50–70% (Mattick et al., 2009); extended-release naltrexone also effective; abstinence-only approaches have high relapse rates (~80–90% within a year).
• Contingency management (Higgins et al., 1994): Providing tangible reinforcers (vouchers, prizes) for verified abstinence — one of the largest effect sizes in addiction treatment (d ≈ 0.42–0.65); particularly effective for stimulant use disorders (no FDA-approved medications exist for cocaine/methamphetamine).
• Motivational interviewing (Miller & Rollnick, 2013): Empathic, non-confrontational approach to resolving ambivalence about change — meta-analyses show modest but significant effects (d ≈ 0.25–0.30); especially effective for engagement and treatment retention.
• CBT for substance use (Carroll, 1998): Relapse prevention — identifying high-risk situations, developing coping skills, challenging substance-related cognitions; moderate effect sizes; benefits persist and may increase after treatment ends.

2. CREDIBLE BUT DEBATED CLAIMS (Tier 2 — Academic / Debated)

2.1 Brain disease model

• NIDA position (Volkow et al., 2016): Addiction is a chronic, relapsing brain disease — neuroimaging reveals measurable changes in brain structure and function; this destigmatizes addiction and supports medical treatment investment.
• Critique (Lewis, 2015; Hart, 2021): The brain disease model: (1) overemphasizes neurobiology at the expense of social, economic, and environmental determinants; (2) most people who meet addiction criteria recover without treatment ("natural recovery" or "maturing out"); (3) brain changes are neuroplastic adaptations, not pathological lesions — learning also reshapes the brain; (4) disease framing may paradoxically reduce agency and self-efficacy.
• Current view: Most researchers accept addiction involves meaningful brain changes but debate whether "brain disease" is the most accurate or helpful framing; biopsychosocial approaches integrate neurobiological, psychological, and social factors.

2.2 Behavioral addictions

• Gambling disorder: The only behavioral addiction in DSM-5 — neuroimaging shows similar reward circuit activation and prefrontal dysfunction as substance addictions; similar cognitive distortions (gambler's fallacy, illusion of control); responds to CBT and naltrexone.
• Internet gaming disorder: DSM-5 Section III (condition requiring further study) — evidence from East Asian cohorts shows compulsive gaming with functional impairment and withdrawal symptoms; whether it constitutes true addiction or reflects other psychopathology is debated.
• Food addiction: Yale Food Addiction Scale identifies binge-like eating patterns associated with highly processed, hyper-palatable foods — neurobiological parallels with substance addiction exist (dopamine, opioid systems) but the construct is controversial; may reflect eating disorder symptoms rather than a distinct addiction.

2.3 12-step programs

• Alcoholics Anonymous: Cochrane meta-analysis (Kelly et al., 2020) found AA/TSF (Twelve-Step Facilitation) was as effective as other therapies (CBT, MET) for producing abstinence and more effective for continuous abstinence at follow-up — the first Cochrane review with positive findings for AA.
• Mechanisms: Social support, identity change ("recovering addict"), accountability, meaning-making, and behavior substitution — peer support replaces drinking network.
• Criticism: Self-selection bias (people who attend may be more motivated); spiritual emphasis alienates secular individuals; abstinence-only philosophy is incompatible with harm reduction; controlled drinking may be appropriate for some.

2.4 Gateway drug hypothesis

The claim that cannabis use leads to harder drugs — association exists but likely reflects: (1) common liability (shared genetic and environmental risk factors), (2) sequencing effects (legal/available drugs tried first), (3) social network exposure; no evidence that cannabis pharmacology causally primes the brain for other drugs.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Psychedelic-assisted addiction treatment

Psilocybin for alcohol use disorder (Bogenschutz et al., 2022 — randomized trial showed significant drinking reduction) and tobacco cessation (Johnson et al., 2014 — 80% abstinence at 6 months in open-label study); ibogaine for opioid withdrawal — promising early results but large confirmatory trials are lacking.

3.2 Smartphone addiction

Whether excessive smartphone use constitutes addiction — reported prevalence varies wildly (5–40%) depending on measurement; may represent habitual behavior, fear of missing out, or comorbid tendencies rather than genuine addiction with tolerance/withdrawal cycles.

4. DUBIOUS OR FRINGE CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Addiction is purely a choice/moral failing

The view that addiction reflects weak character or deliberate vice — contradicted by: heritability data, neuroimaging evidence, the efficacy of pharmacological treatment, and epidemiological data showing addiction distribution correlates with poverty, trauma, and mental illness rather than moral character.

4.2 One use leads to addiction

The scare narrative that a single use of a substance (especially methamphetamine or heroin) causes instant addiction — epidemiological data show that only a minority of people who try any substance develop addiction (~15% for alcohol, ~23% for heroin, ~9% for cannabis; Anthony et al., 1994); vulnerability depends on genetics, environment, and psychological factors.

COUNTER-ARGUMENTS & CRITICISMS

IMAGES

BIBLIOGRAPHY

1. Robinson, Terry E.; Kent C | 1993 | "The Neural Basis of Drug Craving: An Incentive-Sensitization Theory of Addiction" | Brain Research Reviews | ∅ | 18::247–291 | Berridge. . )90013-p | ∅ | doi:10.1016/0165-0173(93 | ∅ | ∅ | ∅
2. Koob, George F.; Michel Le Moal. | 2001 | "Drug Addiction, Dysregulation of Reward, and Allostasis" | Neuropsychopharmacology | ∅ | 24::97–129 | ∅ | ∅ | doi:10.1016/s0893-133x(00)00195-0 | ∅ | ∅ | ∅
3. Goldstein, Rita Z.; Nora D | 2011 | "Dysfunction of the Prefrontal Cortex in Addiction: Neuroimaging Findings and Clinical Implications" | Nature Reviews Neuroscience | ∅ | 12::652–669 | Volkow | ∅ | doi:10.1038/nrn3119 | ∅ | ∅ | ∅
4. Volkow, Nora D., George F | 2016 | "Neurobiologic Advances from the Brain Disease Model of Addiction" | New England Journal of Medicine | ∅ | 374::363–371 | Koob, and A | ∅ | doi:10.1056/nejmra1511480 | ∅ | ∅ | Thomas McLellan
5. Goldman, David, Gabor Oroszi; Francesca Ducci | 2005 | "The Genetics of Addictions: Uncovering the Genes" | Nature Reviews Genetics | ∅ | 6::521–532 | ∅ | ∅ | doi:10.1038/nrg1635 | ∅ | ∅ | ∅
6. Lewis, Marc | 2015 | ∅ | The Biology of Desire: Why Addiction Is Not a Disease | ∅ | ∅ | New York: PublicAffairs | ∅ | ∅ | ∅ | ∅ | ∅
7. Khantzian, Edward J | 1985 | "The Self-Medication Hypothesis of Addictive Disorders" | American Journal of Psychiatry | ∅ | 142::1259–1264 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Mattick, Richard P., et al. : CD002209 | 2009 | "Methadone Maintenance Therapy versus No Opioid Replacement Therapy for Opioid Dependence" | Cochrane Database of Systematic Reviews | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Higgins, Stephen T., et al | 1994 | "Incentives Improve Outcome in Outpatient Behavioral Treatment of Cocaine Dependence" | Archives of General Psychiatry | ∅ | 51::568–576 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Miller, William R.; Stephen Rollnick. . | 2013 | ∅ | Motivational Interviewing | ∅ | ∅ | New York: Guilford Press | 3rd | ∅ | ∅ | ∅ | ∅
11. Carroll, Kathleen M. | 1998 | ∅ | A Cognitive-Behavioral Approach: Treating Cocaine Addiction | ∅ | ∅ | Rockville, MD: NIDA | ∅ | ∅ | ∅ | ∅ | ∅
12. Kelly, John F., et al | 2020 | "Alcoholics Anonymous and 12-Step Facilitation Treatments for Alcohol Use Disorder: A Distillation of a 2020 Cochrane Review" | Addiction | ∅ | 115::1390–1397 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Anthony, James C., Lynn A | 1994 | "Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants" | Experimental and Clinical Psychopharmacology | ∅ | 2::244–268 | Warner, and Ronald C | ∅ | ∅ | ∅ | ∅ | Kessler
14. Nutt, David J., Leslie A | 2010 | "Drug Harms in the UK: A Multicriteria Decision Analysis" | The Lancet | ∅ | 376::1558–1565 | King, and Lawrence D | ∅ | ∅ | ∅ | ∅ | Phillips
15. Bogenschutz, Michael P., et al | 2022 | "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder" | JAMA Psychiatry | ∅ | 79::953–962 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
16. Johnson, Matthew W., Albert Garcia-Romeu; Roland R | 2017 | "Long-Term Follow-Up of Psilocybin-Facilitated Smoking Cessation" | American Journal of Drug and Alcohol Abuse | ∅ | 43::55–60 | Griffiths | ∅ | ∅ | ∅ | ∅ | ∅
17. Hart, Carl L. | 2021 | ∅ | Drug Use for Grown-Ups | ∅ | ∅ | New York: Penguin Press | ∅ | ∅ | ∅ | ∅ | ∅
18. Marlatt, G | 1996 | "Harm Reduction: Come as You Are" | Addictive Behaviors | ∅ | 21::779–788 | Alan | ∅ | ∅ | ∅ | ∅ | ∅
19. Berridge, Kent C | 2009 | "Wanting and Liking: Observations from the Neuroscience and Psychology Laboratory" | Inquiry | ∅ | 52::378–398 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
20. Hall, Wayne; Michael Lynskey | 2005 | "Is Cannabis a Gateway Drug? Testing Hypotheses about the Relationship between Cannabis Use and the Use of Other Illicit Drugs" | Drug and Alcohol Review | ∅ | 24::39–48 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
21. Kelly, John F, et al | 2020 | "Alcoholics Anonymous and other 12-step programs for alcohol use disorder" | Cochrane Database of Systematic Reviews | ∅ | ∅ | ∅ | ∅ | doi:10.1002/14651858.cd012880.pub2 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Document T_2_07 · Created Mar 07, 2026 · TheoriesOfAnything Knowledge Base

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/s0893-133x(00)00195-0. Corpus hygiene campaign, Phase 4, 2026-07-29.

• Document header date — restored to Mar 07, 2026. The header read 2026-03-13 07, 2026: an ISO date had been written over the month name, leaving the day and year. Recovered from a metadata line elsewhere in this document (a changelog row, creation stamp or verification footer) carrying Mar 07, 2026, whose day and year already agreed with the header remnant. Only lines describing this document were consulted; dates appearing in the article text were not used. No date was guessed. Corpus hygiene campaign, Phase 4, 2026-07-29.